The present invention relates to means and methods for combating
myeloproliferative disorders or
lymphoproliferative disorders. The present invention provides human AML-specific binding compounds capable of binding to a
cell surface component of AML cells. Therapeutic applications of the binding compounds against AML are also contemplated.